News

Awamedica Announces Bioequivalence Studies at the AWABETIC Endocrine-Cardiorenal Forum Series

May 7, 2026

Awamedica announced the successful completion of bioequivalence studies for three pharmaceutical products during the AWABETIC Endocrine-Cardiorenal Forum series, organized in collaboration with the Kurdistan Doctors Association (KDA). The announcement was presented to healthcare professionals as part of two scientific meetings held on 7 May 2026 at Crixus Sarsing Hotel, Duhok, and 11 June 2026 at Ashur Resort, Dukan Lake, Sulaymaniyah.

The bioequivalence studies provide evidence that the evaluated Awamedica products demonstrate equivalence to their respective reference medicines in accordance with accepted scientific and regulatory principles. The findings were shared with attending physicians during dedicated scientific sessions to support evidence-based clinical decision-making.

In addition to the bioequivalence announcement, the AWABETIC forums featured discussions on current approaches to endocrine, cardiovascular, and renal disease management, providing a platform for scientific exchange among healthcare professionals. Through these educational meetings, Awamedica continues to support professional collaboration and the dissemination of clinical and regulatory developments relevant to patient care.

Blog

Phase IV Post-Marketing Surveillance: Monitoring Safety After Regulatory Approval

Phase IV studies, also known as post-marketing surveillance, evaluate the long-term safety and effectiveness of medicines after regulatory approval. These studies contribute to ongoing benefit–risk assessment in real-world clinical settings.

Drug Recalls: Regulatory Process and Manufacturer Responsibilities

Drug recalls are structured regulatory actions taken to address quality, safety, or labeling concerns associated with medicinal products. Clear procedures and defined responsibilities ensure patient protection and supply chain integrity.

Safe Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Gastrointestinal and Cardiovascular Considerations

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation management. Appropriate patient selection and risk assessment are essential to minimize gastrointestinal and cardiovascular complications.

How FDA and EMA Issue Safety Alerts: Regulatory Communication in Pharmacovigilance

Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issue safety alerts to communicate emerging risks associated with medicinal products. These alerts support timely risk mitigation and informed clinical decision-making.

1 of 3